Trulieve Cannabis Corp. Subordinate Voting Shares (TRLV) carries a Roarable Rating of D+ (Sell) with 58/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.
As of 2026-11-02, Trulieve Cannabis Corp. Subordinate Voting Shares (NYSE: TRLV) is rated D+ (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 58/100 at a spot price of $10.28 (-3.02% 1D, market cap $2.04B). Pillar breakdown: Fundamental Cash Engine 13/20, Institutional 13F & Options Flow 10/20, Executive Insider Alignment 8/20, FRED Macro Regime Fit 15/20, and SEC Balance-Sheet Forensics 12/20. Across 1016 tracked Health Care issuers, TRLV ranks #197 in composite RQD confidence.
Within the Health Care sector (Medicinal Chemicals and Botanical Products), TRLV carries a Roarable D+ (58/100 RQD), trailing P/E of N/A, gross margin of 60.2%, and ROIC of 12.8%. By comparison, CRON (Cronos Group Inc. Common Share) holds a D grade (51/100 RQD, P/E N/A, ROIC -4.5%, cap $1.24B) and RGC (Regencell Bioscience Holdings Limited) posts a D- grade (38/100 RQD, P/E N/A, ROIC —, cap $3.40B). Among the 5-stock peer group, TRLV leads on earnings multiple (N/A) while TRLV leads on capital efficiency (12.8% ROIC).
Per TRLV's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001754195), Trulieve Cannabis Corp. Subordinate Voting Shares generated $1.18B in revenue (-0.4% YoY), -$116.4M in net income, and $228.6M in free cash flow against $2.70B in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity.. Primary risk factors monitored: Recent SEC filings added new risk-factor disclosures that warrant keeping an eye on margins.. Institutional options positioning shows a 50% call / 50% put premium split.
Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer
FRED Regime × Technicals: 65% of 52W Range • RSI-14 at 48.3 (NEUTRAL RANGE)
SEC XBRL FY 2025 (10-K): 19.4% FCF Margin ($228.6M FCF) & 60.2% Gross Margin
Balance-sheet & 10-K footnote risk deducts 12 pts from forensic ceiling
Even with a 58/100 (D+) score, TRLV faces multiple-compression risk if current valuation multiples re-rate toward historical sector medians or if hyperscaler/enterprise customer concentration slows in upcoming 10-Q filings.
Recent SEC filings added new risk-factor disclosures that warrant keeping an eye on margins.
Dilution & Margin Drag: Cannibal Buyback (-1.24% YoY Shares) — any gross margin slip below 57.7% triggers an automatic RQD downgrade.
Technical & Forensic Kill-Switch: A daily close below the 50D SMA ($11.18) or 200D SMA ($8.83) invalidates the momentum regime and cuts Target Base ($10.28) toward Bear Floor ($8.02).
Trulieve Cannabis Corp. Subordinate Voting Shares (TRLV) dropped -3.02% to $10.28, trading at 65% of its 52-week range ($4.62 – $13.28). Stretched risk/reward at current multiples (13% return on capital) under elevated 10-year interest-rate pressure.
Trulieve Cannabis Corp. (NYSE: TRLV) ("Trulieve" or "the Company"), a leading and top-performing medical cannabis company in the U.S., today announced that Trulieve has received registrations for medical
U.S. stock futures fell, led by Deckers down 9% after mixed results and reduced FY27 guidance. BayCom, ROLR, Trulieve and others also slid premarket.
Cantor Fitzgerald analyst Gabie Ingoglia reiterates Trulieve Cannabis (NYSE:TRLV) with a Overweight and maintains $15 price target.
High energy costs are pushing inflation concerns back into focus after crude oil moved above US$100, and that kind of pressure often pushes investors toward higher risk, higher potential areas like biotechnology. Volatil
On Friday, Trulieve Cannabis (NYSE:TRLV) discussed second-quarter financial results during its earnings call. The full transcript is provided below. This content is powered by Benzinga APIs. For comprehensive financial
ICU Medical, Neogen and Trulieve Cannabis offer distinct growth catalysts as medical products demand benefits from innovation, resilient procedures and evolving market opportunities.
Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).
vs. -0.4% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).
No active Ellis Vennor swing setup published on TRLV today. View full Setup Ledger →
No direct multi-tier Butterfly edges indexed yet for TRLV. Explore sector supply chains on /butterfly.
Across 1016 tracked Health Care securities in the Roarable RQD universe, Trulieve Cannabis Corp. Subordinate Voting Shares (TRLV) ranks #197 by composite RQD confidence (58/100, grade D+) and #258 by equity capitalization ($2.04B). Within this direct 5-issuer industry benchmark cohort, TRLV leads on earnings valuation at N/A trailing P/E, while TRLV leads on capital efficiency and profitability with 12.8% ROIC and 60.2% gross margin. TRLV currently leads its immediate peer cohort in composite quantitative strength at 58/100 (D+).
| Ticker / Company | Roarable Grade | RQD Score | Trailing P/E | Gross Margin | ROIC | 1D Change | Market Cap | Head-to-Head |
|---|---|---|---|---|---|---|---|---|
| TRLV
ACTIVE
Trulieve Cannabis Corp. Subordinate Voting Shares | D+ | 58/100 | — | 60.2% | 12.8% | -3.02% | $2.04B | Benchmark Subject |
| CRON Cronos Group Inc. Common Share | D | 51/100 | — | 42.8% | -4.5% | -1.79% | $1.24B | /cron-vs-trlv → |
| RGC Regencell Bioscience Holdings Limited | D- | 38/100 | — | — | — | -2.19% | $3.40B | /rgc-vs-trlv → |
| DFTX Definium Therapeutics Inc. | D+ | 52/100 | — | — | -32.2% | -4.29% | $5.10B | /dftx-vs-trlv → |
| TLRY Tilray Brands Inc. | E | 20/100 | — | 28.4% | -3.9% | -4.17% | $390.2M | /tlry-vs-trlv → |
In its most recent audited fiscal period (FY2025, filed 2025-12-31), Trulieve Cannabis Corp. Subordinate Voting Shares (TRLV) reported GAAP revenue of $1.18B (-0.4% vs. FY2024 revenue of $1.19B , and +4.6% cumulative change since FY2023) , GAAP net income of -$116.4M, operating cash flow of $272.8M, and free cash flow of $228.6M (+53.6% YoY). On the balance sheet, TRLV closed FY2025 with $2.70B in total assets against $0 in total debt (Altman Z-Score: 1.12, Piotroski F-Score: 6/9).
| Fiscal Period | Filing Date | Revenue | Net Income | Operating Cash Flow | Free Cash Flow | Total Assets | Total Debt |
|---|---|---|---|---|---|---|---|
| FY2025 (FY) | 2025-12-31 | $1.18B | -$116.4M | $272.8M | $228.6M | $2.70B | — |
| FY2024 (FY) | 2024-12-31 | $1.19B | -$155.1M | $271.5M | $148.9M | $2.87B | — |
| FY2023 (FY) | 2023-12-31 | $1.13B | -$526.8M | $201.8M | $201.8M | — | — |
As of 2026-11-02, Trulieve Cannabis Corp. Subordinate Voting Shares (NYSE: TRLV) is rated D+ (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 58/100 at a spot price of $10.28 (-3.02% 1D, market cap $2.04B). Pillar breakdown: Fundamental Cash Engine 13/20, Institutional 13F & Options Flow 10/20, Executive Insider Alignment 8/20, FRED Macro Regime Fit 15/20, and SEC Balance-Sheet Forensics 12/20. Across 1016 tracked Health Care issuers, TRLV ranks #197 in composite RQD confidence.
Within the Health Care sector (Medicinal Chemicals and Botanical Products), TRLV carries a Roarable D+ (58/100 RQD), trailing P/E of N/A, gross margin of 60.2%, and ROIC of 12.8%. By comparison, CRON (Cronos Group Inc. Common Share) holds a D grade (51/100 RQD, P/E N/A, ROIC -4.5%, cap $1.24B) and RGC (Regencell Bioscience Holdings Limited) posts a D- grade (38/100 RQD, P/E N/A, ROIC —, cap $3.40B). Among the 5-stock peer group, TRLV leads on earnings multiple (N/A) while TRLV leads on capital efficiency (12.8% ROIC).
Per TRLV's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001754195), Trulieve Cannabis Corp. Subordinate Voting Shares generated $1.18B in revenue (-0.4% YoY), -$116.4M in net income, and $228.6M in free cash flow against $2.70B in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity.. Primary risk factors monitored: Recent SEC filings added new risk-factor disclosures that warrant keeping an eye on margins.. Institutional options positioning shows a 50% call / 50% put premium split.
TRLV last traded at $10.28 (-3.02% on volume of 1,413,944 shares), positioning the stock -8.05% below its 50-day simple moving average ($11.18) and +16.42% above its 200-day simple moving average ($8.83). Across its 52-week range of $4.62 to $13.28, TRLV sits at the 65.4% percentile with a 14-day RSI of 48.3 (NEUTRAL RANGE) and an implied next-earnings move of ±12.1% ($9.04 to $11.52).
Why TRLV Stock dropped -3.02% Today — RQD Quant Desk Flash. Stretched risk/reward at current multiples (13% return on capital) under elevated 10-year interest-rate pressure.
Per the Roarable RQD rating, TRLV scores 58 out of 100, a letter grade of D+, with a verdict label of "Roarable Sell — Weak Fundamentals / Trim." The five pillars are:
For a prospective investor evaluating the stock today, the combined picture is a mid-range cash-generation profile offset by weak forensic balance-sheet scores and low institutional and insider conviction scores. The verdict label indicates the rating system's view that fundamentals are weak relative to the stock's current standing. This is an analytical reading of the rating's components, not a recommendation to buy or sell.
Trulieve Cannabis Corp. Subordinate Voting Shares (TRLV) is a NYSE-listed issuer classified under the Health Care sector and the Medicinal Chemicals and Botanical Products industry. The source data does not describe its products, customer base, or revenue model beyond this classification. Per the company profile, the market capitalization is $2.0B. Per the SEC financials, reported revenue was $1181.2M for FY 2025.
| Period | Revenue | Operating Income | Net Income | EPS | FCF | Cash | Debt |
|---|---|---|---|---|---|---|---|
| FY 2025 | $1181.2M | $143.5M | $-116.4M | N/A | $228.6M | $255.5M | N/A |
| FY 2024 | $1186.5M | $97.8M | $-155.1M | N/A | $148.9M | $238.8M | N/A |
| FY 2023 | $1129.2M | $-221.6M | $-526.8M | N/A | $201.8M | N/A | N/A |
Per the market data, the gross margin is 60.2%, the operating margin is 12.1%, and the net margin is -9.9%. Per the SEC financials, operating income moved from $-221.6M in FY 2023 to $97.8M in FY 2024 and $143.5M in FY 2025, while net income remained negative in all three periods. Per the Roarable RQD rating, ROIC is 12.8%, and the forensic inputs are an Altman Z-Score of 1.12, a Piotroski F-Score of 6/9, and a Debt/Equity ratio of 0.5. Reported cash was $255.5M for FY 2025 and $238.8M for FY 2024.
Real-time company headlines, analyst actions, and sector developments for Trulieve Cannabis Corp. Subordinate Voting Shares (TRLV) • Click "Debate This Headline" to argue it in the Roar Pit below
Trulieve Cannabis Corp. (NYSE: TRLV) ("Trulieve" or "the Company"), a leading and top-performing medical cannabis company in the U.S., today announced that Trulieve has received registrations for medical
U.S. stock futures fell, led by Deckers down 9% after mixed results and reduced FY27 guidance. BayCom, ROLR, Trulieve and others also slid premarket.
Cantor Fitzgerald analyst Gabie Ingoglia reiterates Trulieve Cannabis (NYSE:TRLV) with a Overweight and maintains $15 price target.
High energy costs are pushing inflation concerns back into focus after crude oil moved above US$100, and that kind of pressure often pushes investors toward higher risk, higher potential areas like biotechnology. Volatil
On Friday, Trulieve Cannabis (NYSE:TRLV) discussed second-quarter financial results during its earnings call. The full transcript is provided below. This content is powered by Benzinga APIs. For comprehensive financial
ICU Medical, Neogen and Trulieve Cannabis offer distinct growth catalysts as medical products demand benefits from innovation, resilient procedures and evolving market opportunities.
Welcome to the TRLV (Trulieve Cannabis Corp. Subordinate Voting Shares) Roar Pit. Current RQD Composite is 58/100 (Roarable Sell — Weak Fundamentals / Trim) in Medicinal Chemicals and Botanical Products. Bulls point to capital efficiency (12.8% ROIC), while bears focus on macro rate sensitivity and margin execution. Pick your side (🐂 Bull or 🐻 Bear) and drop your price target below.
Everyone in here is repeating the bull case on TRLV, but look at what you are paying: current EV/EBITDA multiples with 60.2% gross margins. Unless Trulieve Cannabis Corp. Subordinate Voting Shares expands free cash flow yield next quarter, I would rather wait for a pullback closer to the 200-day moving average before touching this.
Looking at the 5-pillar RQD breakdown on TRLV, the market is fixating on short-term headline noise in Medicinal Chemicals and Botanical Products and ignoring the balance sheet and cash flow trajectory. At $10.60 (52-wk range $4.62 - $13.28), any beat on forward guidance forces shorts and underweight funds to chase.
To protect compute speed and zero-delay Cboe BZX data quality for active members, our current $9.95/month Roarable Pro cohort is 100% full. Join the priority waiting list below and we will notify you the moment the next batch of Pro accounts opens (and lock in your $9.95/mo rate).
Link your personal ChatGPT, Claude Desktop, or Cursor via Roarable's Model Context Protocol (`mcp.roarable.com`) to query all 5,289 stocks, inspect Butterfly supply chains, and trade your `$100K Arena` account.
Interrogate SEC 10-K/10-Q filings on demand and ask custom ticker, valuation, or short-thesis questions directly to any of our 8 specialized AI Quant Analysts.
Command our AI agents to sort and sift 5,289 stocks by custom formulas, follow multi-indicator technical & cash-flow setups, and send you instant Email/SMS breakout & downgrade alerts.
Unlock sub-second Cboe BZX streaming quotes, pre-market/after-hours delta scanners, instant SEC Form 4 insider cluster alerts, and unlimited portfolio stress-testing.
All 8 Roarable Analysts (Mara Quenwick, Devon Kess, Gideon Vane, Eliott Vance, Sorel Thorne, Corin Hale, Tessa Rane, and Felix Orven) are proprietary AI Quant Analysts and automated algorithmic specialists — not human financial advisors, fiduciaries, or registered broker-dealers. While one-to-many daily stock ratings and briefings are free, custom 1-on-1 Q&A, custom AI sifting/indicator alert agents, and personal ChatGPT/Claude MCP connections consume dedicated per-user compute and require a $9.95/month Roarable Pro membership. All AI outputs are for educational and research purposes only and never constitute individualized investment advice.
Enter your Google email below for instant 1-step account activation, daily A–E stock rating alerts, and immediate access to your $100,000.00 Virtual Cash Arena account (100% free — no credit card required).